Impacts of Eligibility Criteria on Trial Participants' Age in Alzheimer's Disease Clinical Trials.

AMIA ... Annual Symposium proceedings. AMIA Symposium Pub Date : 2023-04-29 eCollection Date: 2022-01-01
Aokun Chen, Qian Li, Xing He, Michael S Jaffee, William R Hogan, Fei Wang, Yi Guo, Jiang Bian
{"title":"Impacts of Eligibility Criteria on Trial Participants' Age in Alzheimer's Disease Clinical Trials.","authors":"Aokun Chen, Qian Li, Xing He, Michael S Jaffee, William R Hogan, Fei Wang, Yi Guo, Jiang Bian","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Overly restricted and poorly designed eligibility criteria reduce the generalizability of the results from clinical trials. We conducted a study to identify and quantify the impacts of study traits extracted from eligibility criteria on the age of study populations in Alzheimer's Disease (AD) clinical trials. Using machine learning methods and SHapley Additive exPlanation (SHAP) values, we identified 30 and 34 study traits that excluded older patients from AD trials in our 2 generated target populations respectively. We also found that study traits had different magnitudes of impacts on the age distributions of the generated study populations across racial-ethnic groups. To our best knowledge, this was the first study that quantified the impact of eligibility criteria on the age of AD trial participants. Our research is a first step in addressing the overly restrictive eligibility criteria in AD clinical trials.</p>","PeriodicalId":72180,"journal":{"name":"AMIA ... Annual Symposium proceedings. AMIA Symposium","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148327/pdf/1149.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AMIA ... Annual Symposium proceedings. AMIA Symposium","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Overly restricted and poorly designed eligibility criteria reduce the generalizability of the results from clinical trials. We conducted a study to identify and quantify the impacts of study traits extracted from eligibility criteria on the age of study populations in Alzheimer's Disease (AD) clinical trials. Using machine learning methods and SHapley Additive exPlanation (SHAP) values, we identified 30 and 34 study traits that excluded older patients from AD trials in our 2 generated target populations respectively. We also found that study traits had different magnitudes of impacts on the age distributions of the generated study populations across racial-ethnic groups. To our best knowledge, this was the first study that quantified the impact of eligibility criteria on the age of AD trial participants. Our research is a first step in addressing the overly restrictive eligibility criteria in AD clinical trials.

Abstract Image

阿尔茨海默病临床试验资格标准对试验参与者年龄的影响。
过度限制和设计不当的资格标准会降低临床试验结果的可推广性。我们开展了一项研究,旨在识别和量化从资格标准中提取的研究特征对阿尔茨海默病(AD)临床试验研究人群年龄的影响。利用机器学习方法和 SHapley Additive exPlanation(SHAP)值,我们在 2 个生成的目标人群中分别发现了 30 和 34 个将老年患者排除在 AD 试验之外的研究特征。我们还发现,研究特征对不同种族群体中生成的研究人群的年龄分布具有不同程度的影响。据我们所知,这是第一项量化资格标准对注意力缺失症试验参与者年龄影响的研究。我们的研究为解决注意力缺失症临床试验资格标准限制过多的问题迈出了第一步。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信